8-K

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 16, 2003

AMEDISYS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	0-24260	11-3131700
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

11100 Mead Road, Suite 300, Baton Rouge, LA 70816

(Address of principal executive offices including zip code)

(225) 292-2031

(Registrant’s telephone number, including area code)

ITEM 1. CHANGES IN CONTROL OF REGISTRANT

Not applicable.

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS

Not applicable.

ITEM 3. BANKRUPTCY OR RECEIVERSHIP

Not applicable.

ITEM 4. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT

Not applicable.

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

Not applicable.

ITEM 6. RESIGNATIONS OF REGISTRANTS DIRECTORS

Not applicable.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

  (a) Financial Statements of Business Acquired.

Not applicable.

  (b) Pro Forma Financial Information.

Not applicable.

(c)	Exhibit No.
	99.1 (i) Text of Investor Relations Slide Show in use beginning September 16, 2003
	(i) Filed herewith.

ITEM 8. CHANGE IN FISCAL YEAR

Not applicable.

ITEM 9. REGULATION FD DISCLOSURE

On September 16, 2003, representatives of Amedisys, Inc. (the “Company”) will begin making presentations at investor conferences using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. We are furnishing the text of these slides pursuant to the Securities and Exchange Commission’s Regulation FD. This information is furnished pursuant to Item 9 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1934. The Company expects to use these slides, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during 2003.

By filing this report on Form 8-K and furnishing this information, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the slides is summary information that is intended to be considered in the context of our Securities and Exchange Commission (“SEC”) filings and other public announcements that we may make, by press release or otherwise, from time to time. We undertake no duty or obligation to publicly update or revise the information contained in this report, although we may do so from time to time as our management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

When included in this Current Report on Form 8-K, the words “expects”, “intends”, “anticipates”, “believes”, “estimates”, and analogous expressions are intended to identify forward-looking statements. Such statements inherently are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, among others, general economic and business conditions, current cash flows and operating deficits, debt service needs, adverse changes in federal and state laws relating to the health care industry, competition, regulatory initiatives and compliance with governmental regulations, customer preferences and various other matters, many of which are beyond the Company’s control. These forward-looking statements speak only as of the date of the Current Report on Form 8-K. The Company expressly disclaims any obligation or undertaking to release publicly any updates or any changes in the Company’s expectations with regard thereto or any changes in events, conditions or circumstances on which any statement is based.

ITEM 10. AMENDMENTS TO THE REGISTRANTS CODE OF ETHICS, OR WAIVER OF A PROVISION OF THE CODE OF ETHICS

Not applicable.

ITEM 11. TEMPORARY SUSPENSION OF TRADING UNDER REGISTRANT’S EMPLOYEE BENEFIT PLANS

Not applicable.

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS

Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.
By:	/s/    GREGORY H. BROWNE
	Gregory H. Browne
	Chief Financial Officer

DATE: September 15, 2003

EX-99.1

Amedisys^™

1

Amedisys^™

A Healthy Investment

NASDAQNM: AMED

2

Statements contained in this presentation which are not historical facts are forward-looking statements. These forward-looking statements and all other statements that may be contained in this presentation that are not historical facts are subject to a number of risks and uncertainties, and actual results may differ materially than those forecasted. Such forward-looking statements are estimates reflecting the best judgment of Amedisys, Inc. management based upon currently available information. Certain factors which could affect the accuracy of such forward-looking statements are identified in the public filings made by Amedisys, Inc. with the Securities and Exchange Commission, and forward-looking statements contained herein, or other public statements of Amedisys, Inc. or its management should be considered in light of those factors.

3

Corporate

Overview

4

Corporate Overview

Amedisys is a leading provider of home health care nursing services.

The Company operates 74 home care locations in the southern and southeastern United States.

5

Our Purpose

To assist our patients in maintaining and improving the quality of their lives

Our Strategy

To offer low-cost outcome driven health care at home as an alternative to facility-based care

Our Mission

To become the home care agency of choice in the markets we serve

6

Investment Highlights

• Rapidly growing industry

• Technology focused

• Clear growth strategy

• Operating leverage

• Successful acquisition record

7

Market

Opportunity

8

What is Home Health Care?

“Medical care delivered to a homebound patient by licensed

professionals supervised by the patient’s physician.”

9

What Does Amedisys Offer?

Care in These Areas…

Diabetes	Cardiac	Wound Care
Orthopedics	Cancer	Neurology
Rehabilitation		Post-Surgical
Antibiotic Therapy		Respiratory
Pain Mgt.	Hydration	Malnutrition

10

Largest Home Nursing Company in the South

74 Locations

[MAP]

11

Home Care Growth Drivers

• Trend from facility to non-facility based care

• Consolidation of fragmented industry

• Aging population

12

Positioned in a Growing Industry

[GRAPHIC]

Source: Health, U.S. 1999, Health and Aging Chartbook, U.S. Health and Human Services Dept. [GRAPHIC]

13

Leader in the Largest Industry Segment

[PIE CHART] Nursing Amedisys Gentiva National Home Health Care Infusion Option Care Respiratory Apria Lincare Hospice Odyssey Vistacare

14

Medicare

Overview

15

Medicare Overview

Prospective Payment System (PPS)

• PPS commenced October 1, 2000

• PPS is a capitated payment system

• PPS is based on per episode payments

• Current CMS expenditure is $10 billion

• Medicare accounts for 90% of AMED revenue

• Requires careful episode management

16

Reimbursement Outlook

• Inflation adjustment effective Oct. 1^st each year

– 3.03% in 2003

– 2.00% to 3.00% in 2004

• Potential legislation

– Higher reimbursement for rural patients

– Reduction in inflation adjustment

– Small patient co-pay

17

Financial

Performance

18

Financial Highlights

• Revenue increased 18% to $129 million in 2002

• June Quarter EPS of $0.16

• Stronger balance sheet

• 9.7 million shares outstanding

19

Financial Performance

Revenue Growth

[GRAPHIC]

20

Financial Performance

[GRAPHIC]

21

Financial Performance

Strengthened Balance Sheet

[GRAPHIC]

22

Growth

Strategy

23

Clear and Identifiable Growth Strategy...Internal

• Expand service area with start-ups

• Enhance physician relationships

• Develop strategic hospital partnerships

24

Clear and Identifiable Growth

Strategy ... Disciplined Acquisitions

• Expand within geographic footprint

• Target hospital based and multi-site agencies

– Compatible payor mix

– Underperforming agencies

– Reasonable pricing

25

Successful Record of Integrating Acquisitions

Precision Home Health	April 1998	Louisiana
Columbia HCA	November 1998	Southern States
Northwest Home Health	October 2000	Georgia
Mid-Florida Home Health	November 2000	Florida
Seton Home Health Services	April 2001	Alabama
HealthCalls	June 2001	South Carolina
Christus Spohn Home Health	April 2002	Texas
Baylor All Saints Home Care	August 2002	Texas
Metro Home Health	August 2003	Louisiana

26

Metro Home Health Acquisition

• Strong market presence in Southeast Louisiana

• Talented and aggressive management team

• Revenue of $17 M

• Expected to be accretive

– In 2003 $0.03 to $0.04

– In 2004 $0.07 to $0.10

• Internally financed

27

Technology...

Information System Initiatives

• Automatic scheduling

• Scanning technology for assessments

• Real time episode analysis

• Centralized review of quality indicators

• Web based HR system

• Executive information system

28

Long Term Revenue Growth Potential

Internal Growth	=	Episode Growth	+	Payment Increase*	15	%
		13%		2%
Acquisitions					15	%

Long Term Revenue Growth Potential 30%

*Etstimated Medicare Payment Increase from 2003 forward

29

Earnings Guidance

• September Quarter 2003

– $ 0.16 to $0.19

• Fiscal Year 2003

– $ 0.63 to $0.67

• Fiscal Year 2004

– Objective of 20% plus growth

30

Leadership Team

Executive Team	Board of Directors
William F.Borne,	William F. Borne, Chairman
Founder, CEO	Ronald A. LaBorde
Larry R. Graham,	Jake L. Netterville
Chief Operating Officer	David R. Pitts
Gregory H. Browne,	Peter R. Ricchiuti
Chief Financial Officer	Independent Directors, Elected in 1997

31

Why Invest in Amedisys?

• Rapidly growing industry

• Technology focused

• Clear growth strategy

• Operating leverage

• Successful acquisition record

32

Amedisys^™

A Healthy Investment

NASDAQNM: AMED

33